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Recent evidence indicates that inhibition of histone
acetyltransferases may be a primary cause of cellu-
lar pathogenesis in polyglutamine diseases such as
Huntington disease; the results raise the possibility
that pharmacologic manipulation of protein acetyla-
tion levels could be of therapeutic benefit.
Nine fatal neurodegenerative diseases are known to
be caused by mutation in polyglutamine-encoding
CAG tracts. These include Huntington disease,
Kennedy disease (SBMA), six spinocerebellar ataxias
(SCAs) and dentatorubral pallidoluysian atrophy [1].
The lengths of CAG tracts in genes susceptible to
expansion are polymorphic in the unaffected popula-
tion. In the Huntington disease gene, the ‘normal’
range is 6 to 34 CAGs. In general, it appears that
tracts of 37 or more CAGs cross a pathogenic thresh-
old, acquiring a propensity to further expansion and
encoding proteins with neurotoxic activity [2].
There is general agreement that a root cause of
polyglutamine disease is interference by  expanded
polyglutamine (polyQ) tracts in cellular pathways. This
pathogenic mechanism likely involves aberrant inter-
actions between expanded polyQ regions and essen-
tial cellular proteins. But we are only beginning to
understand in molecular detail the nature, number and
relative importance of these polyQ-sensitive path-
ways. Cellular processes that have received attention
as being potentially affected by polyQ toxicity include:
protein folding, proteasomal degradation, vesicular
traffic, mitochondrial energy metabolism and tran-
scription. As pieces of the polyglutamine puzzle fall
into place, we are now seeing glimpses of a cellular
picture of what is likely to be a complex disease
mechanism.
Transcription in Polyglutamine Disease
Evidence is accumulating that dysfunction in
transcriptional activation and coactivation may play a
central role in polyglutamine pathogenesis [3]. An
early and enduring model for pathogenesis is based
on the observation that proteins with expanded polyQ
tracts have reduced solubility and a propensity to
form aggregates with amyloid properties. Such aggre-
gates have been observed in numerous transgenic
disease models, and in brain tissue from affected
patients. The tendency of expanded polyQ regions to
self-associate led to the reasonable expectation that
other cellular proteins, particularly those with polyQ
tracts, could co-aggregate with the expanded disease
proteins, and that loss of function in these cellular pro-
teins might have a role in pathogenesis. This has been
referred to as a ‘sequestration’ model of pathology.
Sequestration of a polyQ-containing transcription
factor, the TATA-binding protein (TBP), to polyQ inclu-
sions was first demonstrated in spinocerebellar ataxia
type-3 disease brain tissue [4]. CAG expansion in the
TBP gene itself has now been shown to cause a dom-
inant cerebellar ataxia [5].
An early indication that histone acetylation dysfunc-
tion might be involved in polyQ disease was the
observation that CREB-binding protein (CBP), a
histone acetyltransferase, aggregates with a protein
containing an expanded polyQ tract when the two
proteins are co-expressed in cultured cells [6]. The
presence of CBP in polyQ aggregates was greatly
diminished when a domain containing a polyQ tract
was deleted from its carboxyl terminus. At the time,
there was no evidence suggesting that CBP function
is compromised in polyQ disease.
While the conclusions drawn from this study
emphasized the general notion of sequestration of
non-expanded polyQ proteins, the choice of CBP as a
test case was prescient. It was subsequently shown in
cell-culture models that CBP co-localizes in polyQ
aggregates of expanded forms of the androgen recep-
tor (mutated in Kennedy disease) and of ataxin-3
(mutated in spinocerebellar ataxia-3) [7]. Importantly,
CBP was also localized to nuclear polyQ aggregates
in human tissue from a Kennedy disease patient. CBP
was similarly localized to aggregates of huntingtin —
product of the Huntington disease gene — in brain
tissue of transgenic mice [8]. In human brain tissue
from Huntington disease and dentatorubral palli-
doluysian atrophy patients, CBP was found to have
redistributed from its normal diffuse nuclear localiza-
tion into polyglutamine aggregates, and levels of
soluble CBP were shown to be markedly reduced in
brain extracts from Huntington disease patients [9].
Multiple lines of investigation strongly implicate
loss of CBP function as a key cellular defect in polyg-
lutamine disease [10]. The idea that cellular CBP
activity may be limiting is supported by the fact that
mutation in a single copy of the CBP gene, resulting
in loss of histone acetyltransferase activity, causes
Rubinstein-Taybi syndrome, a familial disorder char-
acterized by mental retardation and dysmorphic
abnormalities [11]. PolyQ expression has been shown
to interfere with CBP-mediated transcription and to
promote cell death in tissue culture models of
Kennedy disease, Huntington disease and denta-
torubral pallidoluysian atrophy, and this can be sig-
nificantly mitigated by overexpression of CBP
[7,9,12]. Taken together, these data indicate that
interaction of expanded polyQ with CBP is involved in
the pathogenesis of a diverse group of polyQ dis-
eases and may therefore represent a unifying mecha-
nism for polyQ toxicity. These data also suggest that
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interventions that augment CBP function could have
significant therapeutic benefit (Figure 1).
Targets and Therapy
With CBP and the protein acetylation pathway, we
may have arrived at a point of having drug targets
involved in a primary mechanism of polyQ pathogen-
esis. The question arises as to how best to translate
this knowledge into developing therapeutic interven-
tions. While the success of using CBP overexpression
to rescue polyQ toxicity in cell models suggests that a
gene therapy approach could be of benefit, it would
be preferable to use a small molecule drug that
exerted a similar effect. Currently, there are no reports
of small molecules that augment histone acetylase
function, however there are a number of well
characterized histone deacetylase (HDAC) inhibitors
(Figure 2) [13]. As protein acetylation levels result from
a balance of acetylase and deacetylase activities, it
might be possible to compensate for the diminished
acetylation levels caused by expanded polyQ by
pharmacologic inhibition of histone deacetylase
function.
Three recent studies [12,14,15] have provided
evidence that HDAC inhibition could be a viable
therapeutic strategy. In a transgenic Drosophila model,
progressive neurodegeneration and early adult lethality
caused by expanded polyQ expression were arrested
by feeding flies HDAC inhibitors, either butyrate or
suberoylanilide hydroxamic acid (SAHA) [14]. These
authors also demonstrated that polyQ interacts
directly with the conserved histone acetyltransferase
domain of CBP and the related enzyme P/CAF, and
that polyQ directly inhibits acetyltransferase activities
in vitro. Direct interaction of polyQ with the active site
of these acetyltransferases was a surprising result,
demonstrating that inhibition of CBP activity does not
require polyQ–polyQ interaction.
In a second study [15], transcript profiles in a yeast
model expressing nuclear-expanded polyQ were found
to be similar to those observed with yeast bearing
mutations in genes encoding histone acetyltrans-
ferase components. PolyQ-mediated repression of the
most severely affected gene, PHO84, was mitigated
by the HDAC inhibitor trichostatin A (TSA). Finally, in a
cell culture model of Kennedy disease, cell death
caused by expression of expanded polyQ-containing
androgen receptor was reduced by treating the cells
with SAHA or TSA [12].
Because of their ability to promote growth arrest,
terminal differentiation and apoptosis in tumor cells,
HDAC inhibitors are being investigated as drugs for
the treatment of cancer [13]. The anti-proliferative
properties of SAHA and related compounds are
thought to be due in part to their ability to induce
transcription of the gene for p21WAF1, a protein impor-
tant for growth arrest [16]. Intriguingly, a huntingtin
fragment containing expanded polyQ was shown to
repress transcription from the p21WAF1 promoter [8].
As the cells affected in the polyQ diseases are primar-
ily non-dividing adult neurons, the benefit of HDAC
inhibitors might not be due to their anti-proliferative
activity. It is known that expanded polyQ expression
leads to repression of many transcripts [15,17,18].
Some of these genes may be repressed through mech-
anisms involving polyQ-mediated effects on protein
acetylation. The therapeutic activity of HDAC
inhibitors in models of polyQ toxicity could potentially
work by restoring levels of key transcripts that encode
proteins necessary for neuronal survival.
In moving HDAC inhibitors toward the next stage of
evaluation, it will be of great interest to see what effect
these compounds have in mouse models of polyQ
disease. When using models such as those described
here to understand human disease processes, it is
important to consider that the natural history of polyg-
lutamine disease is likely to involve significant periods
of neuronal dysfunction prior to cell death. Protective
effects mediated by CBP replacement and/or HDAC
inhibition in cell culture or fly models can clearly
prevent cell death, but we have little information about
what effect these interventions have on function as
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Figure 1. A potential role for protein
acetlyation in the cellular pathology of
polyglutamine disease.
Inhibition of the histone acetyltransferase
activity of CREB-binding protein (and
possibly other HAT enzymes) by expanded
polyglutamine causes inappropriate sup-
pression of histone acetylation levels. This
results in abnormal patterns of gene
expression and cell toxicity. Chemical
inhibition of histone deacetylase enzymes
compensate for the toxic effects of polyg-
lutamine by enhancing levels of acety-
lated histones.
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cells cope with polyglutamine stress. Chronic neu-
ronal dysfunction may account for much of what a
patient experiences as polyglutamine disease, and
therefore preventing or arresting dysfunction should
be considered as a distinct therapeutic goal. For this
reason, it would be desirable to include experimental
assays of neuronal function when evaluating these
and other potential therapeutics.
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Figure 2. Histone deacetylase inhibitors.
The short chain fatty acid butyrate and the hydroxamic acids
TSA and SAHA, all inhibitors of histone deacetylases, have
been tested in models of polyglutamine toxicity, as discussed in
the text. Members of the latter class of HDAC inhibitors contain
a hydroxamic acid group, two polar groups separated by a
hydrophobic spacer, and a terminal hydrophobic group [13].
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